What Does Progression-Free Survival Actually Mean for You?
When your doctor talks about progression-free survival, or PFS, they mean the length of time during and after treatment when the disease does not get worse. For carcinoid tumor patients, this is one of the most important numbers in cancer care. It tells you how long a treatment may keep your tumor stable — not growing, not spreading to new places.
PFS is not the same as a cure. It is a measure of control. And for people living with a slow-growing carcinoid tumor, disease control for months or even years can make a real difference in day-to-day life. It can mean fewer symptoms, less pain, and more time doing the things that matter to you.
The NETTER-1 Trial: The Key Study for Carcinoid Patients
Most of what we know about Lu-177 DOTATATE and carcinoid tumors comes from a large clinical trial called NETTER-1. This was a phase 3 randomized controlled trial — the gold standard in cancer research. It enrolled 229 patients with advanced, progressive midgut neuroendocrine tumors, which includes most carcinoid tumors of the small bowel and surrounding digestive organs.
Patients were divided into two groups. Half received Lu-177 DOTATATE — four infusions, one every eight weeks — along with a standard-dose somatostatin analog. The other half received a higher dose of the somatostatin analog alone, which was the best available treatment at the time. Neither group received any additional experimental therapy during the study.
The results showed significant benefit. In the Lu-177 DOTATATE group, the median progression-free survival was not reached at the time of the primary analysis. In plain terms, this means more than half of the patients treated with Lu-177 DOTATATE had not yet experienced disease progression when the study data was reviewed. In the control group, the median PFS was just 8.5 months.
At the 20-month mark, 65.2% of patients in the Lu-177 DOTATATE group had not seen their disease progress. In the control group, only 10.8% were still progression-free at that same point. The hazard ratio was 0.18 — meaning the risk of disease progression or death was reduced by roughly 82% compared to high-dose somatostatin analog therapy alone.
These findings led to FDA approval of Lu-177 DOTATATE in January 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults, including carcinoid tumors of the midgut.
What "Median PFS Not Reached" Means in Plain Language
This phrase often puzzles patients. When researchers say the median PFS was "not reached," it means that when they closed the primary analysis, more than half the patients in the Lu-177 DOTATATE group were still alive without disease progression. Because the majority had not yet progressed, it was impossible to calculate a midpoint. There simply was not enough data on the other side of the curve to define one.
This is positive news. It indicates that many patients in the treatment group stayed stable for longer than the trial's planned observation window. Follow-up analyses later provided more details, and those results confirmed that Lu-177 DOTATATE may provide a long period of disease control for carcinoid patients.
Long-Term Follow-Up: What the Overall Survival Data Showed
When the final NETTER-1 overall survival analysis was completed and presented at an ASCO oncology meeting in 2021, it added important context to the PFS findings. Median overall survival in the Lu-177 DOTATATE group was 48.0 months — roughly four years — compared to 36.3 months in the control group.
Many patients in the control group were permitted to cross over and receive Lu-177 DOTATATE after their disease progressed. This crossover makes it harder to see the full survival difference between the two groups. Yet even with that crossover, the overall survival data still favored the Lu-177 DOTATATE arm. This suggests the true long-term benefit may be larger than the numbers directly show.
What the NETTER-2 Trial Added to the Picture
A more recent study called the NETTER-2 trial examined Lu-177 DOTATATE in patients with higher-grade (G2 and G3) advanced GEP-NETs who had not yet received prior somatostatin analog therapy. Based on data available on NIH research databases, the trial found a median progression-free survival of 22.8 months in the Lu-177 DOTATATE group, compared to 8.5 months in the group receiving octreotide LAR alone.
NETTER-2 enrolled a somewhat different patient population than NETTER-1 — higher-grade tumors and earlier in the treatment course — but it provides a broader picture. Across different grades and settings, Lu-177 DOTATATE may offer disease control in the range of 20 to 24 months or more. For patients who receive it earlier in their disease history, the period of stability may extend even further.
What Real-World Data Shows Outside of Clinical Trials
Clinical trials enroll carefully selected patients who meet strict eligibility criteria. They often exclude people with certain health conditions, very advanced disease, or prior heavy treatment. Real-world evidence — gathered from treatment centers managing everyday patients — provides a broader view of how Lu-177 DOTATATE performs in practice.
Patients with midgut carcinoid tumors tend to respond well to Lu-177 DOTATATE according to reviews on NIH's medical reference database, with outcomes similar to what NETTER-1 showed. Outcomes may differ for carcinoid tumors located in other parts of the body, such as the lungs or stomach.
Real-world data reports median PFS ranging from about 14 months to over 34 months across mixed NET populations, depending on tumor characteristics, prior therapies, organ function, and how intensely the tumor absorbs the radiotracer on imaging. These numbers vary widely between studies and patient groups, which is why individual discussions with your own oncology team matter so much.
These figures are not guarantees for any one person. But they show a pattern: for many carcinoid patients who meet the eligibility criteria for PRRT, Lu-177 DOTATATE may offer a window of stability lasting years rather than just months.
What Factors May Affect How Long Your Tumor Stays Stable?
No two carcinoid tumors behave exactly the same way. Several factors may influence how long Lu-177 DOTATATE keeps your disease under control:
- Somatostatin receptor (SSTR) expression: The more strongly your tumor expresses SSTR2 on a Ga-68 DOTATATE PET scan, the more precisely the therapy may target it. Higher tracer uptake on that scan tends to be associated with better response.
- Tumor grade: Well-differentiated, slow-growing carcinoid tumors (grade 1 and low grade 2) generally respond better and stay stable longer than higher-grade tumors.
- Extent of disease: Patients with fewer or smaller tumors often see longer periods of stability than those with very widespread disease at the time of treatment.
- Line of therapy: Research suggests that receiving Lu-177 DOTATATE earlier in your treatment journey — before many other therapies have been tried — may be linked to a longer period of disease control.
- Kidney and liver function: Healthy kidneys allow you to safely receive the full planned dose of Lu-177 DOTATATE. Healthy liver function matters too, since many carcinoid tumors spread to the liver. Both affect both eligibility and response.
- Tumor location: The strongest evidence base from NETTER-1 is in midgut carcinoid tumors. Tumors in other locations may respond differently, and your oncologist will weigh this carefully.
Your oncologist and nuclear medicine specialist will review all of these factors when discussing what you might reasonably expect. If you want to understand how doctors use imaging and lab results to track whether the therapy is working, the article What Can I Realistically Expect from Lu-177 DOTATATE — How Do Doctors Measure Whether It Is Working? walks through each monitoring tool your care team uses.
What "Stable Disease" Actually Looks Like in Practice
Stability does not always mean the tumor disappears completely. In PRRT studies, the most common type of response to Lu-177 DOTATATE is classified as stable disease — meaning the tumor has not grown or spread. Tumor shrinkage, called a partial or complete response, is also possible but happens in a smaller share of patients.
For many carcinoid tumor patients, stable disease is an important outcome. It means the treatment is working. The tumor is controlled. Because carcinoid tumors often grow slowly, a long period of stable disease can preserve your quality of life, protect your organ function, and keep future treatment options open.
Many patients also notice that carcinoid syndrome symptoms — including diarrhea, flushing, and abdominal cramps caused by excess hormone release from the tumor — improve or become less frequent during or after Lu-177 DOTATATE therapy. Research published alongside the NETTER-1 trial confirmed that quality of life was better preserved in the treatment group. This symptom benefit can be just as important as what shows up on a scan.
What Happens If the Tumor Eventually Progresses?
Lu-177 DOTATATE does not maintain control forever in every patient. Over time, some tumors may begin to grow again. This is called progression. When it happens, your care team will review the next steps. These might include a repeat course of PRRT (if your kidneys can safely tolerate additional treatment), other systemic therapies such as targeted agents, liver-directed procedures, or enrollment in a clinical trial.
The fact that a tumor eventually progresses does not mean the treatment failed. Every period of disease control has real clinical value. For many carcinoid patients, that window of stable disease spans one, two, or even three or more years — time that matters for quality of life and for keeping future options open.
If you are wondering whether Lu-177 DOTATATE can be combined with the somatostatin analog you may already be taking, the article Can I Combine Lu-177 DOTATATE with My Somatostatin Analog for Carcinoid Tumor? What Does the Evidence Say About Dual Therapy? reviews what the research shows about using both approaches together.
Setting Realistic Expectations for Your Personal Timeline
It is natural to want a specific number — how many months before the tumor grows again? Medicine rarely offers that kind of precision for any individual. What the data provides is a range of likely outcomes across a population of patients who are similar to you. Your personal timeline will depend on the specific factors that only your oncologist can properly assess for your case.
What the evidence clearly shows is that for many patients with somatostatin receptor-positive carcinoid tumors, Lu-177 DOTATATE may offer better disease control compared to somatostatin analog therapy alone. During that period of control, research consistently shows that quality of life is often maintained or improved.
If you are in the early stages of exploring PRRT, understanding what happens between infusion cycles is also important. The article Traveling Between Lu-177 DOTATATE Infusions: What Patients Need to Know About Radiation Safety and Logistics answers many common practical questions about the day-to-day journey through a full course of treatment.
When to Talk to Your Doctor
Before starting Lu-177 DOTATATE, ask your oncologist or nuclear medicine specialist what your personal progression-free survival outlook may look like, given your tumor grade, receptor expression results, and treatment history. Useful questions include: What does my Ga-68 DOTATATE PET result suggest about my likely response? How will we monitor whether the treatment is keeping the tumor stable? And what options would we consider if the tumor begins growing again?
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How long does Lu-177 DOTATATE typically keep a carcinoid tumor stable?
The NETTER-1 phase 3 trial found that the median progression-free survival for patients treated with Lu-177 DOTATATE was not reached at the time of the primary analysis, meaning more than half the patients had not yet progressed. At the 20-month mark, 65.2% of the treatment group remained progression-free, compared to 10.8% in the control group. Real-world data across mixed NET populations suggests many patients experience stable disease for anywhere from 14 to more than 34 months, depending on individual factors such as tumor grade, somatostatin receptor expression level, and prior treatment history.
What does it mean when researchers say the median PFS was 'not reached'?
It means that when the trial's primary analysis was completed, more than 50% of patients in the Lu-177 DOTATATE group had still not experienced disease progression. Because the majority had not yet progressed, it was impossible to calculate a midpoint for the survival curve. This is considered a favorable finding. It indicates that a large proportion of patients stayed stable for longer than the study's primary observation window, suggesting the true median may be quite high.
Does my tumor grade or somatostatin receptor level affect how long the treatment will work?
Yes, both factors may influence the duration of disease control. Well-differentiated, lower-grade carcinoid tumors (grade 1 and low grade 2) with high somatostatin receptor expression on a Ga-68 DOTATATE PET scan tend to respond better and stay stable for longer periods. Patients with more extensive disease, higher tumor grades, or lower receptor expression may see shorter periods of benefit. Your oncologist will review your full picture — including scan results, lab values, and kidney and liver function — when discussing realistic expectations for your case.
What happens when Lu-177 DOTATATE eventually stops working?
When disease progression is confirmed after completing PRRT, your care team will review the available next steps. Depending on your overall health, organ function, and prior treatment history, these may include a repeat course of Lu-177 DOTATATE, other systemic therapies such as targeted agents or chemotherapy, liver-directed procedures such as embolization, or enrollment in a clinical trial. The fact that progression eventually occurs does not mean the treatment failed — every period of stable disease has clinical value, and maintaining control extends the time available for future options.
Will Lu-177 DOTATATE also help with carcinoid syndrome symptoms like flushing and diarrhea?
Many patients report improvement in carcinoid syndrome symptoms during or after Lu-177 DOTATATE therapy. Because the treatment targets the tumor directly, reducing its ability to release excess hormones, symptoms such as flushing, diarrhea, and abdominal cramping may become less frequent or less severe over time. Research alongside the NETTER-1 trial confirmed that quality of life was better maintained in the treatment group compared to the control group. Talk to your oncologist about what symptom changes you might realistically expect based on your individual tumor burden and receptor expression.
Is Lu-177 DOTATATE used for all carcinoid tumor locations, or only certain ones?
The FDA approved Lu-177 DOTATATE for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, and the strongest clinical trial evidence comes from midgut carcinoid tumors of the small bowel (the NETTER-1 trial). Its use in bronchial (lung) carcinoid tumors and other locations is an active area of research, but the evidence base is smaller. Your eligibility will be guided primarily by your Ga-68 DOTATATE PET scan results, tumor pathology, and kidney and liver function rather than location alone, so it is worth discussing your specific situation with an experienced NET specialist.